Author: van de Veerdonk, Frank L; Netea, Mihai G; van Deuren, Marcel; van der Meer, Jos WM; de Mast, Quirijn; Brüggemann, Roger J; van der Hoeven, Hans
Title: Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome Cord-id: 2yozikdd Document date: 2020_4_27
ID: 2yozikdd
Snippet: COVID-19 patients can present with pulmonary edema early in disease. We propose that this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the B1R. Without ACE2 acting as a guardian to inactivate the ligands of B1R, the lung environment is prone for local vascular leakage leading to an
Document: COVID-19 patients can present with pulmonary edema early in disease. We propose that this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the B1R. Without ACE2 acting as a guardian to inactivate the ligands of B1R, the lung environment is prone for local vascular leakage leading to angioedema. Here, we hypothesize that a kinin-dependent local lung angioedema via B1R and eventually B2R is an important feature of COVID-19. We propose that blocking the B2R and inhibiting plasma kallikrein activity might have an ameliorating effect on early disease caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS). In addition, this pathway might indirectly be responsive to anti-inflammatory agents.
Search related documents:
Co phrase search for related documents- ace inhibitor and low molecular weight: 1
- active enzyme and low molecular weight: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date